旧酪氨酸激酶抑制剂及新的胃肠道肿瘤治疗手段

Title:Old Tyrosine Kinase Inhibitors and Newcomers in Gastrointestinal Cancer Treatment

Volume: 16 Issue: 2

Author(s): Giordani Erika, Zoratto Federica, Strudel Martina, Papa Anselmo, Rossi Luigi, Minozzi Marina and Caruso Davide, Zaccarelli Eleonora, Verrico Monica and Tomao Silverio

Affiliation:

关键词: 批准的酪氨酸激酶抑制剂，疗效数据，实验酪氨酸激酶抑制剂，胃肠道肿瘤，个性化治疗。

摘要: Gastrointestinal cancer treatment is based more on molecular biology that has provided increasing knowledge about cancer pathogenesis on which targeted therapy is being developed. Precisely, targeted therapy is defined as a “type of treatment that uses drugs, such as monoclonal antibodies or tyrosine kinase inhibitors, to identify and attack specific cancer cells”. Nowadays, the United States Food and Drug Administration has approved many targeted therapies for gastrointestinal cancer treatment, as many are in various phases of development as well. In a previous review we discussed the main monoclonal antibodies used and studied in gastrointestinal cancer. In addition to monoclonal antibodies, tyrosine kinase inhibitors represent another class of targeted therapy and following the approval of imatinib for gastrointestinal stromal tumours, other tyrosine kinase inhibitors have been approved for gastrointestinal cancers treatment such as sunitinib, regoragenib, sorafenib and erlotinib. Moving forward, the purpose of this review is to focus on the efficacy data of main tyrosine kinase inhibitors commonly used in the personalized treatment of each gastrointestinal tumour and to provide a comprehensive overview about experimental targeted therapies ongoing in this setting.

Cite this article as:

Giordani Erika, Zoratto Federica, Strudel Martina, Papa Anselmo, Rossi Luigi, Minozzi Marina and Caruso Davide, Zaccarelli Eleonora, Verrico Monica and Tomao Silverio , Old Tyrosine Kinase Inhibitors and Newcomers in Gastrointestinal Cancer Treatment, Current Cancer Drug Targets 2016; 16 (2) . https://dx.doi.org/10.2174/1568009615666150817120712